Last reviewed · How we verify
VIT-45
VIT-45 is a vitamin D analog that enhances immune function and reduces inflammation through vitamin D receptor signaling.
VIT-45 is a vitamin D analog that enhances immune function and reduces inflammation through vitamin D receptor signaling. Used for Secondary hyperparathyroidism in patients with chronic kidney disease.
At a glance
| Generic name | VIT-45 |
|---|---|
| Also known as | ferric carboxymaltose |
| Sponsor | American Regent, Inc. |
| Drug class | Vitamin D analog |
| Target | Vitamin D receptor (VDR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
VIT-45 acts as a vitamin D receptor agonist, modulating immune cell differentiation and promoting anti-inflammatory responses. By binding to the vitamin D receptor, it enhances regulatory T cell function and reduces pro-inflammatory cytokine production, potentially benefiting autoimmune and inflammatory conditions.
Approved indications
- Secondary hyperparathyroidism in patients with chronic kidney disease
Common side effects
- Hypercalcemia
- Hyperphosphatemia
- Nausea
Key clinical trials
- Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome (PHASE4)
- The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department (PHASE4)
- EFFICACY OF IV VERSUS ORAL IRON IN THE TREATMENT OF IRON DEFICIENCY ANEMIA DURING PREGNANCY (PHASE1)
- The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension (PHASE4)
- Iron Infusion in Patients Undergoing Transcatheter Aortic Valve Implantation (PHASE4)
- Comparison of Oral vs Intravenous Iron Therapy for the Treatment of Postpartum Anemia (NA)
- Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency (PHASE3)
- An Open Study on the Efficacy of Iron Therapy Using iv Iron Relative to Oral Iron for Increasing LV Systolic Function (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VIT-45 CI brief — competitive landscape report
- VIT-45 updates RSS · CI watch RSS
- American Regent, Inc. portfolio CI